» Articles » PMID: 32107486

Assessment of the Nail Penetration of Antifungal Agents, with Different Physico-chemical Properties

Overview
Journal PLoS One
Date 2020 Feb 29
PMID 32107486
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Onychomycosis, or fungal nail infection, is a common fungal infection largely caused by dermatophyte fungi, such as Trichophyton rubrum or Trichophyton mentagrophytes, which affects a significant number of people. Treatment is either through oral antifungal medicines, which are efficacious but have significant safety concerns, or with topical antifungal treatments that require long treatment regimens and have only limited efficacy. Thus, an efficacious topical therapy remains an unmet medical need. Among the barriers to topical delivery through the nail are the physico-chemical properties of the antifungal drugs. Here, we explore the ability of a range of antifungal compounds with different hydrophilicities to penetrate the nail. Human nail discs were clamped within static diffusion (Franz) cells and dosed with equimolar concentrations of antifungal drugs. Using LC-MS/MS we quantified the amount of drug that passed through the nail disc and that which remained associated with the nail. Our data identified increased drug flux through the nail for the more hydrophilic compounds (caffeine as a hydrophilic control and fluconazole, with LogP -0.07 and 0.5, respectively), while less hydrophilic efinaconazole, amorolfine and terbinafine (LogP 2.7, 5.6 and 5.9 respectively) had much lower flux through the nail. On the other hand, hydrophilicity alone did not account for the amount of drug associated with/bound to the nail itself. While there are other factors that are likely to combine to dictate nail penetration, this work supports earlier studies that implicate compound hydrophilicity as a critical factor for nail penetration.

Citing Articles

Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.

Prajapati S, Jain A, Bajpai M RSC Adv. 2025; 15(10):7799-7825.

PMID: 40070389 PMC: 11895809. DOI: 10.1039/d5ra00387c.


Transungual Penetration and Antifungal Activity of Prescription and Over-the-Counter Topical Antifungals: Ex Vivo Comparison.

Elabbasi A, Kadry A, Joseph W, Elewski B, Ghannoum M Dermatol Ther (Heidelb). 2024; 14(9):2495-2507.

PMID: 39133361 PMC: 11393267. DOI: 10.1007/s13555-024-01237-6.


The Preparation and Evaluation of a Hydrochloride Hydrogel Patch with an Iontophoresis-Assisted Release of Terbinafine for Transdermal Delivery.

Li M, Chen X, Su X, Gao W Gels. 2024; 10(7).

PMID: 39057479 PMC: 11275388. DOI: 10.3390/gels10070456.


Chronic paronychia associated with fluconazole use in two pediatric patients with coccidioidomycosis.

Price N, Cormack E, Matthias K, Shehab K IDCases. 2024; 37:e02026.

PMID: 39045033 PMC: 11265586. DOI: 10.1016/j.idcr.2024.e02026.


Formulation and Antimycotic Evaluation of Colloidal Itraconazole-Loaded Metered Dose Sprays for Treating Superficial Mycoses.

Uronnachi E, Nakpheng T, Gugu T, Srichana T AAPS PharmSciTech. 2024; 25(6):156.

PMID: 38981986 DOI: 10.1208/s12249-024-02879-7.


References
1.
Gupta A, Kohli Y, Batra R . In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med Mycol. 2005; 43(2):179-85. DOI: 10.1080/13693780410001731583. View

2.
Walters K, Flynn G, MARVEL J . Physicochemical characterization of the human nail: permeation pattern for water and the homologous alcohols and differences with respect to the stratum corneum. J Pharm Pharmacol. 1983; 35(1):28-33. DOI: 10.1111/j.2042-7158.1983.tb04258.x. View

3.
Elewski B . Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998; 11(3):415-29. PMC: 88888. DOI: 10.1128/CMR.11.3.415. View

4.
Matsuda Y, Sugiura K, Hashimoto T, Ueda A, Konno Y, Tatsumi Y . Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis. PLoS One. 2016; 11(7):e0159661. PMC: 4956321. DOI: 10.1371/journal.pone.0159661. View

5.
Elkeeb R, Alikhan A, Elkeeb L, Hui X, Maibach H . Transungual drug delivery: current status. Int J Pharm. 2009; 384(1-2):1-8. DOI: 10.1016/j.ijpharm.2009.10.002. View